New York, July 10, 2026, 13:08 EDT
Moderna Inc. NASDAQ:MRNA shares fell 11.3% to $67.91 at 12:53 p.m. EDT on Friday, erasing about $3.4 billion in market value. The vaccine maker had traded as high as $78.47, leaving the stock 13.5% below its intraday peak.
The decline puts a sharper focus on Thursday’s European Union announcement. Six countries may order as many as 24 million doses of Moderna’s mRESVIA respiratory syncytial virus vaccine over four years, but the contract sets no minimum purchase. The Commission disclosed neither a price nor a total contract value; a framework agreement sets terms for later orders rather than booking the full volume at signing.
That distinction matters after a fast rerating. Moderna shares gained 48% in June and closed Monday at $81.80, their highest finish since August 2024; Friday’s quote was almost 17% lower. Alec Stranahan, an analyst at BofA Securities, wrote that the stock had “overshot implied value from upcoming data readouts” and saw “more risk to the downside.” His $38 price target — an analyst estimate of where the stock may trade — is 44% below Friday’s price. Barron’s
Three disclosed figures frame the investor issue:
| Item | Headline amount | Contractual certainty |
|---|---|---|
| EU mRESVIA framework | Up to 24 million doses | No minimum; up to four years |
| Patent settlement payment | $950 million | Noncontingent; due on or before July 8 |
| Additional appeal exposure | Up to $1.3 billion | Contingent on the appeal outcome |
The settlement filing describes the $950 million payment as noncontingent and the additional $1.3 billion as conditional. It does not establish whether the first payment had been completed by Friday.
The cash side is more immediate. Moderna held $7.5 billion in cash and investments on March 31, making the $950 million obligation equal to about 12.7% of that balance. The company had already recorded the related first-quarter expense and projected year-end cash and investments of $4.5 billion to $5 billion, so the deadline was known rather than a fresh earnings charge.
The broader biotechnology market was weak, but much less so:
| Security | Midday price | Friday move |
|---|---|---|
| Moderna Inc. NASDAQ:MRNA | $67.91 | -11.3% |
| iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) | $191.56 | -2.9% |
| GSK plc ADR NYSE:GSK | $52.52 | +0.1% |
| Pfizer Inc. NYSE:PFE | $24.25 | 0.0% |
Moderna fell about 3.9 times as much as the biotechnology fund, while its two main RSV rivals were flat to slightly higher. That spread suggests stock-specific position cutting after the rally, though it does not prove a single trigger.
Commercially, mRESVIA has considerable ground to cover. Moderna’s last annual product-specific figure was $25 million of mRESVIA sales in 2024; its 2025 release did not break out the product and said most of its $1.9 billion in total revenue came from COVID-19 vaccines. GSK reported £0.6 billion of 2025 Arexvy sales, while Pfizer recorded $1.033 billion for Abrysvo. The reporting periods and currencies differ, but the scale gap remains large.
Two near-term checks are now in view. Moderna is due to report second-quarter results on July 31 after guiding revenue of $50 million to $100 million, and the U.S. Food and Drug Administration has an August 5 decision target for mRNA-1010, Moderna’s seasonal flu vaccine. Those are firm dates; the timing and size of EU orders are not.
But the setup cuts both ways. The stock could recover if participating countries order quickly, the flu shot wins approval or oncology data beat expectations. The downside is that the EU minimum is zero, weak second-quarter sales could reinforce cash-burn concerns, and the patent appeal could trigger as much as $1.3 billion in additional settlement cash.
For now, the price action suggests investors are assigning more value to firm orders and cash preservation than to procurement ceilings. The EU agreement opens a sales channel. It does not yet show how many doses will ship, when they will ship or what Moderna will earn.
